Table 18

Sitagliptin compared with an active agent

Author, yearChange in A1c from baseline at (%)Change in FPG from baseline at (mg/dL)Change in PPG from baseline at (mg/dL)Percent achieving A1c <7%Change in weight from baseline at (kg)aPercent requiring rescue medication (%)
12 weeks12 weeks12 weeks12 weeks12 weeks12 weeks
Scott, 200753−0.54−0.76−18.2−24.8−48.4b−66.4bNRNR+0.4+0.9NRNR
24 weeks24 weeks24 weeks24 weeks24 weeks24 weeks
Goldstein, 200754−0.66−0.82−1.13−17.5−27.3−29.3−51.9−53.4−78.02023380−0.9−1.1211712

Data on weight not reported in the publication were provided by the manufacturer.


P<0.01 compared with baseline.

Abbreviations: Glip, glipizide; M1, metformin 1000 mg/day; M2, metformin 2000 mg/day; S100, sitagliptin 100 mg daily; NR, not reported.

From: Results

Cover of Drug Class Review: Newer Drugs for the Treatment of Diabetes Mellitus
Drug Class Review: Newer Drugs for the Treatment of Diabetes Mellitus: Final Report [Internet].
Norris SL, Lee NJ, Severance S, et al.
Portland (OR): Oregon Health & Science University; 2008 Aug.
Copyright © 2008, Oregon Health & Science University, Portland, Oregon.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.